Search research articles
Contact Us
Filters
Showing results (481-490 of 501) with videos related to
Page
of 51
Sort By:
Nature Communications
|
October 30, 2022
Genome-wide rare variant score associates with morphological subtypes of autism spectrum disorder
Ada J S Chan, Worrawat Engchuan, Miriam S Reuter, et al.
Blood Cancer Journal
|
November 5, 2020
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Jonathan L Kaufman, Meletios A Dimopoulos, Darrell White, et al.
Nature Medicine
|
August 15, 2023
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Alexander M Lesokhin, Michael H Tomasson, Bertrand Arnulf, et al.
ACS Medicinal Chemistry Letters
|
November 20, 2020
Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3Kγ Inhibitors
Dillon H Miles, Xuelei Yan, Rhiannon Thomas-Tran, et al.
Sports Medicine (Auckland, N.Z.)
|
July 15, 2021
Managing Travel Fatigue and Jet Lag in Athletes: A Review and Consensus Statement
Dina C Janse van Rensburg, Audrey Jansen van Rensburg, Peter M Fowler, et al.
Science Translational Medicine
|
April 5, 2023
T<sub>STEM</sub>-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models
Deborah Meyran, Joe Jiang Zhu, Jeanne Butler, et al.
Journal of Medicinal Chemistry
|
May 23, 2025
Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer Therapy
Dillon H Miles, Manjunath Lamani, Srinivas Reddy Paladugu, et al.
Blood
|
November 10, 2021
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC
Elise A Olsen, Sean Whittaker, Rein Willemze, et al.
Internal Medicine Journal
|
May 28, 2021
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement
Georgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, et al.
Lancet (London, England)
|
June 11, 2017
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H Miles Prince, Youn H Kim, Steven M Horwitz, et al.
Page
of 51
Search research articles
Search
Showing results (481-490 of 501) with videos related to
Sort By:
Page
of 51
Nature Communications
|
October 30, 2022
Genome-wide rare variant score associates with morphological subtypes of autism spectrum disorder
Ada J S Chan, Worrawat Engchuan, Miriam S Reuter, et al.
Blood Cancer Journal
|
November 5, 2020
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Jonathan L Kaufman, Meletios A Dimopoulos, Darrell White, et al.
Nature Medicine
|
August 15, 2023
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Alexander M Lesokhin, Michael H Tomasson, Bertrand Arnulf, et al.
ACS Medicinal Chemistry Letters
|
November 20, 2020
Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3Kγ Inhibitors
Dillon H Miles, Xuelei Yan, Rhiannon Thomas-Tran, et al.
Sports Medicine (Auckland, N.Z.)
|
July 15, 2021
Managing Travel Fatigue and Jet Lag in Athletes: A Review and Consensus Statement
Dina C Janse van Rensburg, Audrey Jansen van Rensburg, Peter M Fowler, et al.
Science Translational Medicine
|
April 5, 2023
T<sub>STEM</sub>-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models
Deborah Meyran, Joe Jiang Zhu, Jeanne Butler, et al.
Journal of Medicinal Chemistry
|
May 23, 2025
Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer Therapy
Dillon H Miles, Manjunath Lamani, Srinivas Reddy Paladugu, et al.
Blood
|
November 10, 2021
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC
Elise A Olsen, Sean Whittaker, Rein Willemze, et al.
Internal Medicine Journal
|
May 28, 2021
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement
Georgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, et al.
Lancet (London, England)
|
June 11, 2017
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H Miles Prince, Youn H Kim, Steven M Horwitz, et al.
Page
of 51